.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB10_Amrubicin.Amrubicin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB10_Amrubicin.Amrubicin| name: | Amrubicin | |
| ATC code: | L01DB10 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 40 | mg |
| volume of distribution: | 54.0 | L |
| clearance: | 40.9 | L/h/m2 |
| other parameters in model implementation | ||
Amrubicin is a synthetic anthracycline antitumor agent used in the treatment of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). It acts primarily as a topoisomerase II inhibitor. Amrubicin is approved for use in some countries, such as Japan, primarily for lung cancer treatment.
Pharmacokinetic parameters were assessed in adult Japanese patients with advanced non-small cell lung cancer and small cell lung cancer following intravenous administration.